LDN is being investigated in multiple conditions characterized by chronic inflammation, immune dysfunction, or persistent pain. These include fibromyalgia, some autoimmune conditions, chronic pain syndromes, and certain inflammatory pathologies.
Its mechanism is complex and involves modulation of opioid receptors and reduced microglial activation, which may contribute to reducing neurogenic inflammation and central sensitization.